New Dual-Action drug aims to tackle obesity without diabetes

NCT ID NCT07685808

Not yet recruiting Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests an experimental drug, olatorepatide, which mimics natural hormones to help with weight loss. It involves 360 adults with overweight or obesity (but not diabetes) who receive different doses or a placebo. Researchers will check safety, side effects, how the drug works in the body, and how much weight participants lose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olatorepatide (a GLP-1/GIP receptor agonist)
What this could lead to: If successful, this could provide a new medication option for weight loss in people with overweight or obesity, potentially improving health outcomes.
What could go wrong: This is an early-phase trial, so the drug may not prove effective or safe in larger studies. Side effects are possible, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Body Weight Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT OR OBESITY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.